Vancouver, BC, August 2, 2019--recision NanoSystems (PNI), a biotechnology company pioneering innovative solutions for the development of genetic nanomedicines for gene and cell therapy used in oncology, rare disease and infectious disease, announced the official commercial launch of NxGen Blaze and NxGen blaze+ at the 2019 CRS Annual Meeting & Exposition, in Valencia, Spain.
|